BioStock: Stayble Therapeutics CEO sums up Q2 and looks ahead

During the second quarter, Stayble Therapeutics focused primarily on the recruitment of patients to the ongoing phase IIb study with the injection treatment STA363. In addition, key employees have been recruited to the company and a high presence has been maintained towards potential partners. In an interview with BioStock, Stayble Therapeutics’ CEO Andreas Gerward talks about the most important events of the second quarter and the company’s plans for the autumn. 

 Read the full article at biostock.se: 

https://www.biostock.se/en/2021/08/stayble-therapeutics-ceo-sums-up-q2-and-looks-ahead/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se